A Major CYP2D6 Autoepitope in Autoimmune Hepatitis Type 2 and Chronic Hepatitis C is a Three-dimensional Structure Homologous to Other Cytochrome P450 Autoantigens

Background and Aims. Chronic hepatitis C is a systemic disease and type 2 diabetes mellitus (T2DM) belongs to more common extrahepatic. The aim of this study was to (i) explore the prevalence of impaired fasting glucose (IFG) and T2DM in patients with chronic hepatitis C, (ii) explore the effect of direct acting antivirals (DAA) treatment on the glycemia, and (iii) explore the factors that modulate the effect of DAA treatment on glycemia in patients with chronic hepatitis C.Methods. We performed a longitudinal retrospective observational study focused on the patients undergoing DAA treatment of chronic hepatitis C. Data about glycemia, history of diabetes, hepatitis C virus, treatment, and liver status, including elastography, were obtained at baseline (before treatment start), at the end of treatment and 12 weeks after the end of treatment. Patients were treated with various regimens of direct acting antivirals.Results. We included 370 patients; 45.9% had F4 fibrosis. At baseline, the prevalence of T2DM increased with the degree of fibrosis (F0-F2 14.4%, F3 21.3%, and F4 31.8%, p=0.004). Fasting glycemia also increased with the degree of fibrosis (F0-F2 5.75±0.18 F3 5.84±0.17, and F4 6.69±0.2 mmol/L, p=0.001). We saw significant decrease of glycemia after treatment in all patients, but patients without T2DM or IFG from 6.21±0.12 to 6.08±0.15 mmol/L (p=0.002). The decrease was also visible in treatment experienced patients and patients with Child-Pugh A cirrhosis.Conclusion. We confirmed that the prevalence of either T2DM or IFG increases in chronic hepatitis C patients with the degree of fibrosis. The predictive factors for T2DM were, besides F4, fibrosis also higher age and BMI. Significant decrease of fasting glycemia after the DAA treatment was observed in the whole cohort and in subgroups of patients with T2DM, IFG, cirrhotic, and treatment experienced patients.

Download Full-text

Chronic hepatitis C associated with anti-liver/kidney microsome-1 antibody is not a subgroup of autoimmune hepatitis

Journal of Gastroenterology ◽

10.1007/bf02936953 ◽

1997 ◽

Vol 32 (6) ◽

pp. 769-776 ◽

Cited By ~ 16

Author(s):

Hiroshi Miyakawa ◽

Eriko Kitazawa ◽

Kazuhiro Abe ◽

Naomi Kawaguchi ◽

Hirotoshi Fuzikawa ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Autoimmune Hepatitis ◽

Chronic Hepatitis C ◽

Kidney Microsome

Download Full-text

Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis C

ACG Case Reports Journal ◽

10.14309/crj.2015.74 ◽

2015 ◽

Vol 2 (1) ◽

pp. 247-249 ◽

Cited By ~ 2

Author(s):

Chetan Rathi ◽

Nirav Pipaliya ◽

Dhaval Choksi ◽

Pathik Parikh ◽

Meghraj Ingle ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Autoimmune Hepatitis ◽

Chronic Hepatitis C ◽

Pegylated Interferon ◽

Interferon Α

Download Full-text

Risk of autoimmune hepatitis reactivation in patients with chronic hepatitis C and autoimmune hepatitis treated with direct-acting antivirals

Polish Archives of Internal Medicine ◽

10.20452/pamw.4442 ◽

2019 ◽

Cited By ~ 1

Author(s):

Katarzyna Fleischer-Stępniewska ◽

Weronika Rymer ◽

Marcin Stanisław Inglot ◽

Małgorzata Zalewska ◽

Brygida Knysz ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Autoimmune Hepatitis ◽

Chronic Hepatitis C ◽

Direct Acting Antivirals ◽

Direct Acting

Download Full-text

DIABETES MELLITUS;

The Professional Medical Journal ◽

10.29309/tpmj/2013.20.02.629 ◽

2013 ◽

Vol 20 (02) ◽

pp. 220-226

Author(s):

GHAZANFAR ALI SINDHU, ◽

SADAF NAZ, ◽

FRAZ SAEED QURESHI, ◽

Zaheer Ahmed, ◽

Tamur Islam,

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Hcv Infection ◽

Hcv Rna ◽

Newly Diagnosed

Introduction: Hepatitis C virus (HCV) is a major cause of chronic liver disease, cirrhosis and hepatocellular carcinoma(HCC). HCV infection and type 2 diabetes are two common disorders with a high impact on health worldwide. There is growing evidenceto support the concept that HCV infection is a risk factor for developing type 2 Diabetes Mellitus. Both insulin resistance and diabetes canadversely affect the course of chronic hepatitis C, and lead to poor response to antiviral therapy and increased incidence of Hepatocellularcarcinoma. Objective: The objective of the study was to assess the frequency of type 2 Diabetes mellitus in newly diagnosed chronichepatitis C patients presenting in Allied hospital Medical unit II during six month period. Design: Cross sectional study. Setting: Medicalunit-II, Allied Hospital, Faisalabad. Period: 01-08-2009 to 28-02-2010. Material and methods: All newly diagnosed patients of chronichepatitis C on the basis of PCR for HCV-RNA were included in the study. Fasting and two hours postprandial blood sample were tested.Diabetes Mellitus was labeled as per slandered. Results: Out of 180 patients with CHC 19 (10.6%) were found to have Diabetes mellituswhile 161(89.4%) were non-diabetics. Conclusions: There is close association in the development of type 2 diabetes mellitus in patientswith chronic hepatitis C.

Download Full-text